Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

Fitusiran

Aliases
Fitusiran (SAR439774), SAR439774

6 clinical trials

3 indications

Indication
Hemophilia
Indication
Hemophilia A
Indication
Hemophilia B
Clinical trial
An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX
Status: Active (not recruiting), Estimated PCD: 2026-11-05
Clinical trial
An Open-label, Single-arm Treatment Study to Investigate the Safety and Tolerability of Switching From Emicizumab to Fitusiran Prophylaxis in Male Participants Aged ≥18 Years of Age With Severe Hemophilia A, With or Without Inhibitors
Status: Recruiting, Estimated PCD: 2026-09-19
Clinical trial
A Phase 3, Single-arm, Multicenter, Multinational, Open-label, One-way Crossover Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged ≥ 12 Years With Severe Hemophilia A or B With or Without Inhibitory Antibodies to Factor VIII or IX
Status: Recruiting, Estimated PCD: 2026-04-15
Clinical trial
ATLAS-PEDS: An Open-label, Multinational Study of Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B
Status: Active (not recruiting), Estimated PCD: 2028-02-15
Clinical trial
An Open-label Extension Study of Subcutaneously Administered Fitusiran in Patients With Moderate or Severe Hemophilia A or B Who Have Participated in a Previous Clinical Study With Fitusiran
Status: Completed, Estimated PCD: 2023-03-21
Clinical trial
ATLAS-PPX: an Open-label, Multinational, Switching Study to Describe the Efficacy and Safety of Fitusiran Prophylaxis in Patients With Hemophilia A and B Previously Receiving Factor or Bypassing Agent Prophylaxis.
Status: Completed, Estimated PCD: 2022-01-20